Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00032747 | Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT). | PHASE2 | COMPLETED | 338 | — | — | Aug 1, 2001 | Feb 1, 2003 | Jun 17, 2008 | 9 | United States, Canada +1 |
| Name | Type | Description |
|---|---|---|
| Vasopressin V2 Receptor Antagonist | DRUG | - |
* Men or women with chronic heart failure (NYHA Class IIIB and IV). * Women must be post-menopausal or surgically sterilized; they cannot be pregnant or nursing. * Age 21 to 80 years. * Chronic heart failure of at least 3 months duration. For 2 months prior to screening, patients must have had sympt...